Cargando…

Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis

AIMS: To describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction, yet some HCM patients develop impaired systolic function t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserstrum, Yishay, Larrañaga‐Moreira, José M., Martinez‐Veira, Cristina, Itelman, Edward, Lotan, Dor, Sabbag, Avi, Kuperstein, Rafael, Peled, Yael, Freimark, Dov, Barriales‐Villa, Roberto, Arad, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288812/
https://www.ncbi.nlm.nih.gov/pubmed/35488723
http://dx.doi.org/10.1002/ehf2.13914
_version_ 1784748531538460672
author Wasserstrum, Yishay
Larrañaga‐Moreira, José M.
Martinez‐Veira, Cristina
Itelman, Edward
Lotan, Dor
Sabbag, Avi
Kuperstein, Rafael
Peled, Yael
Freimark, Dov
Barriales‐Villa, Roberto
Arad, Michael
author_facet Wasserstrum, Yishay
Larrañaga‐Moreira, José M.
Martinez‐Veira, Cristina
Itelman, Edward
Lotan, Dor
Sabbag, Avi
Kuperstein, Rafael
Peled, Yael
Freimark, Dov
Barriales‐Villa, Roberto
Arad, Michael
author_sort Wasserstrum, Yishay
collection PubMed
description AIMS: To describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction, yet some HCM patients develop impaired systolic function that is associated with worse outcomes. METHODS AND RESULTS: Our registry included 1328 HCM patients from two centres in Spain and Israel. Patients with normal baseline ventricular function were matched, and a competing‐risk analysis was performed to find factors associated with HCMr development. Patient records were reviewed to recognize clinically significant events that occurred closely before the development of HCMr. Genetic data were collected in patients with HCMr. A composite of all‐cause mortality or ventricular assist device (VAD)/heart transplantation was assessed according to ventricular function. Median age was 56, and 34% were female patients. HCMr at evaluation was seen in 37 (2.8%) patients, and 46 (3.5%) developed HCMr during median follow up of 9 years. HCMr was associated with younger age of diagnosis, poor functional class, and ventricular arrhythmia. Atrial fibrillation, pacemaker implantation, and baseline left ventricular ejection fraction (LVEF) of ≤55% were significant predictors of future HCMr development, while LV obstruction predicted a lower risk. Genetic testing performed in 53 HCMr patients, identifying one or more pathogenic variant in 38 (72%): most commonly in myosin binding protein C (n = 20). Six of these patients had an additional pathogenic variant in one of the sarcomere genes. Patients with baseline HCMr had a higher risk (hazard ratio 6.4, 4.1–10.1) for the composite outcome and for the individual components. Patients who developed HCMr in the course of the study had similar mortality but a higher rate of VAD/heart transplantation compared with HCM with normal LVEF. CONCLUSIONS: Hypertrophic cardiomyopathy with reduced ejection fraction is associated with heart failure and poor outcome. Arrhythmia, cardiac surgery, and device implantation were commonly documented prior to HCMr development, suggesting they may be either a trigger or the result of adverse remodelling. Future studies should focus on prediction and prevention of HCMr.
format Online
Article
Text
id pubmed-9288812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92888122022-07-19 Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis Wasserstrum, Yishay Larrañaga‐Moreira, José M. Martinez‐Veira, Cristina Itelman, Edward Lotan, Dor Sabbag, Avi Kuperstein, Rafael Peled, Yael Freimark, Dov Barriales‐Villa, Roberto Arad, Michael ESC Heart Fail Original Articles AIMS: To describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction, yet some HCM patients develop impaired systolic function that is associated with worse outcomes. METHODS AND RESULTS: Our registry included 1328 HCM patients from two centres in Spain and Israel. Patients with normal baseline ventricular function were matched, and a competing‐risk analysis was performed to find factors associated with HCMr development. Patient records were reviewed to recognize clinically significant events that occurred closely before the development of HCMr. Genetic data were collected in patients with HCMr. A composite of all‐cause mortality or ventricular assist device (VAD)/heart transplantation was assessed according to ventricular function. Median age was 56, and 34% were female patients. HCMr at evaluation was seen in 37 (2.8%) patients, and 46 (3.5%) developed HCMr during median follow up of 9 years. HCMr was associated with younger age of diagnosis, poor functional class, and ventricular arrhythmia. Atrial fibrillation, pacemaker implantation, and baseline left ventricular ejection fraction (LVEF) of ≤55% were significant predictors of future HCMr development, while LV obstruction predicted a lower risk. Genetic testing performed in 53 HCMr patients, identifying one or more pathogenic variant in 38 (72%): most commonly in myosin binding protein C (n = 20). Six of these patients had an additional pathogenic variant in one of the sarcomere genes. Patients with baseline HCMr had a higher risk (hazard ratio 6.4, 4.1–10.1) for the composite outcome and for the individual components. Patients who developed HCMr in the course of the study had similar mortality but a higher rate of VAD/heart transplantation compared with HCM with normal LVEF. CONCLUSIONS: Hypertrophic cardiomyopathy with reduced ejection fraction is associated with heart failure and poor outcome. Arrhythmia, cardiac surgery, and device implantation were commonly documented prior to HCMr development, suggesting they may be either a trigger or the result of adverse remodelling. Future studies should focus on prediction and prevention of HCMr. John Wiley and Sons Inc. 2022-04-30 /pmc/articles/PMC9288812/ /pubmed/35488723 http://dx.doi.org/10.1002/ehf2.13914 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Wasserstrum, Yishay
Larrañaga‐Moreira, José M.
Martinez‐Veira, Cristina
Itelman, Edward
Lotan, Dor
Sabbag, Avi
Kuperstein, Rafael
Peled, Yael
Freimark, Dov
Barriales‐Villa, Roberto
Arad, Michael
Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
title Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
title_full Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
title_fullStr Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
title_full_unstemmed Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
title_short Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
title_sort hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288812/
https://www.ncbi.nlm.nih.gov/pubmed/35488723
http://dx.doi.org/10.1002/ehf2.13914
work_keys_str_mv AT wasserstrumyishay hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT larranagamoreirajosem hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT martinezveiracristina hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT itelmanedward hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT lotandor hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT sabbagavi hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT kupersteinrafael hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT peledyael hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT freimarkdov hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT barrialesvillaroberto hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis
AT aradmichael hypokinetichypertrophiccardiomyopathyclinicalphenotypegeneticsandprognosis